Clinical trial · Interventional
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
Whole-Body MRI in the Evaluation of Pediatric Malignancies
NCT00072488CI-TRIAL-00003520unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease. PURPOSE: This clinical trial is studying whole-body MRI to see how well it works compared to standard imaging procedures in detecting distant metastases in patients with solid tumors or lymphoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| computed tomography | Procedure | — | UNRESOLVED |
| magnetic resonance imaging | Procedure | — | UNRESOLVED |
| positron emission tomography | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Confirmed diagnosis OR newly diagnosed mass strongly suspected to represent 1 of the following: * Rhabdomyosarcoma * Ewing's sarcoma family of tumors * Neuroblastoma * Hodgkin's lymphoma * Non-Hodgkin's lymphoma * All imaging examinations (e.g., CT scan, MRI, or scintigraphy) must be performed within 14 days of each other and within 2 months of any diagnostic or operative procedure * Whole body MRI and positron emission tomography (PET) scanning (if PET scan is being done) must be done before treatment * Prior CT scan, conventional MRI, bone scintigraphy, gallium scintigraphy, or meta-iodobenzylguanidine (MIBG) scintigraphy performed at outside institutions allowed provided the same technical standards specified in this study were practiced * Bone scintigraphy required for patients with neuroblastoma, rhabdomyosarcoma, or other sarcomas * Gallium scintigraphy not required in lymphoma patients if PET scan is performed * No CNS primary tumor PATIENT CHARACTERISTICS: Age * 21 and under Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Cardiovascular * No active cardiac pacemakers Other * Not pregnant or nursing * No prior malignancy * No uncontrolled diabetes mellitus (for patients undergoing optional PET) * Patients with controlled diabetes mellitus must have a fasting blood glucose no greater than 200 mg/dL * No contraindications to MRI or CT scan (e.g., intracranial vascular clips) PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Prior biopsy or surgery allowed provided no more than 2 months has passed since the procedure
References
Publications (0)
Data not yet available
No reference posted for this study.